We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
A Retrospective Review of Metastatic or Recurrent Uterine Sarcomas Treated with Ifosfamide and Doxorubicin (IMA).
- Authors
Aksoy, Sercan; Hizli, Deniz; Sarici, Saynur; Öcalan, Reyhan; Köse, M. Faruk; Güler, Nilüfer
- Abstract
The prognosis of metastatic uterine sarcoma is poor with median survival reported between 4 to 26 months. We evaluated the efficacy and toxicity of ifosfamide (I), mesna (M) and doxorubicin (A) (IMA) chemotherapy regimen retrospectively in patients with metastatic or recurrent uterine sarcomas. Forty-two patients were enrolled in this study. The median age was 53 years (range, 18-72). Thirty-seven patients were assessable for response and survival; forty patients were assessable for toxicity. A total of 162 cycles of chemotherapy were introduced and for each patient and median number of chemotherapy cycles were 4 (range, 1-6). We observed complete response (CR) in 3 patients; partial response (PR) in 14 patients. Objective RR was 46% (95% CI, 30% to 62%). The median progression-free survival time of the responders was 8.0 months (range, 4-35). The median progression- free survival time of all patients was 5.0 months. Febrile neutropenia was encountered in 6 patients. Dose modifications were required in 4 patients due to myelotoxicity. Central nervous system (CNS) toxicity was observed in three patients. IMA regimen has moderate anti-tumor activity (46%) with acceptable toxicity in patients with recurrent or metastatic uterine sarcomas.
- Subjects
CANCER treatment; SARCOMA; DOXORUBICIN; ANTHRACYCLINES; DRUG therapy; FEBRILE neutropenia; INFECTION; CANCER prognosis
- Publication
UHOD: International Journal of Hematology & Oncology / Uluslararasi Hematoloji Onkoloji Dergisi, 2008, Vol 18, Issue 3, p129
- ISSN
1306-133X
- Publication type
Article